Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

BACKGROUND. The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-class, tumor-specific antibody-drug conjugate that...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Reardon, David A., Lassman, Andrew B., van den Bent, Martin, Kumthekar, Priya, Merrell, Ryan, Scott, Andrew M., Fichtel, Lisa, Sulman, Erik P., Gomez, Erica, Fischer, JuDee, Lee, Ho-Jin, Munasinghe, Wijith, Xiong, Hao, Mandich, Helen, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle D., Gan, Hui K.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570193/
https://ncbi.nlm.nih.gov/pubmed/28039367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now257
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items